Human and animal model studies suggest CXCL13 is a potential biomarker in primary Sjögren’s syndrome (pSS). CXCL13 has not been studied in Indian patients with pSS. pSS cases classified by American European Consensus Group (AECG) or American college of Rheumatology(ACR) 2012 criteria, attending rheumatology clinic between July 2014 and July 2015 were included. Hospital staff and healthy, non-blood related family members of patients constituted the control group. pSS cases underwent clinical evaluation, laboratory investigations, ESSDAI and ESSPRI scoring. Unstimulated saliva was collected by the spitting method. Salivary and serum CXCL13 were quantified by indirect ELISA. CXCL13 positivity was determined using Receiver Operator Characteristic (ROC) curve. STATA13.1 (StataCorpLP,Texas,USA) software was used for statistical analysis. In this study, 45 pSS cases and 42 healthy controls were recruited. In pSS, median levels of serum CXCL13, but not salivary CXCL13 was significantly higher as compared to the corresponding levels in healthy controls (p < 0.001). Using cutoff of 43.03 pg/ml obtained by ROC, serum CXCL13 positivity was seen in 31/43(72.1%) cases and 10/34 (29.4%) controls, respectively. Serum CXCL13 levels among pSS patients on treatment, treatment naïve patients and healthy controls were statistically different. Serum CXCL13 positivity was associated with oral symptoms (p = 0.02), ocular signs (p = 0.03) and hyperglobulinemia (p = 0.01). There was no association of salivary CXCL13 level with any of the clinical variables. While serum CXCL13 was elevated in pSS, salivary CXCL13 was not. In conclusion, serum CXCL13 positivity was found to be associated with oral symptoms, ocular signs and hyperglobulinemia in pSS.
Saliva Serum CXCL13 Sjogren’s syndrome India
This is a preview of subscription content, log in to check access
We acknowledge the funding received from Christian Medical College (CMC) fluid research grant for the study.
Compliance with ethical standards
Conflict of interest
The authors report that they have no conflicts of interests.
This study was approved by the Institutional review board (IRB) & Ethics committee and was conducted in accordance with the Helsinki declaration of 1975, as revised in 2008.
Informed consent has been obtained from all participants.
Shiboski SC, Shiboski CH, Criswell LA et al (2012) American College of Rheumatology classification criteria for Sjögren’s syndrome: a data-driven, expert consensus approach in the Sjögren’s International Collaborative Clinical Alliance cohort. Arthritis Care Res 64:475–487CrossRefGoogle Scholar
Xanthou G, Polihronis M, Tzioufas AG, et al (2001) “Lymphoid” chemokine messenger RNA expression by epithelial cells in the chronic inflammatory lesion of the salivary glands of Sjögren’s syndrome patients: possible participation in lymphoid structure formation. Arthritis Rheum 44:408–418. https://doi.org/10.1002/1529-0131(200102)44:2<408::AID-ANR60>3.0.CO;2-0CrossRefPubMedGoogle Scholar
Luther SA, Lopez T, Bai W et al (2000) BLC expression in pancreatic islets causes B cell recruitment and lymphotoxin-dependent lymphoid neogenesis. Immunity 12:471–481CrossRefPubMedGoogle Scholar
Amft N, Curnow SJ, Scheel-Toellner D et al (2001) Ectopic expression of the B cell-attracting chemokine BCA-1 (CXCL13) on endothelial cells and within lymphoid follicles contributes to the establishment of germinal center-like structures in Sjögren’s syndrome. Arthritis Rheum 44:2633–2641CrossRefPubMedGoogle Scholar
Salomonsson S, Larsson P, Tengnér P et al (2002) Expression of the B cell-attracting chemokine CXCL13 in the target organ and autoantibody production in ectopic lymphoid tissue in the chronic inflammatory disease Sjögren’s syndrome. Scand J Immunol 55:336–342CrossRefPubMedGoogle Scholar
Seror R, Gottenberg JE, Devauchelle-Pensec V et al (2013) European league against rheumatism Sjögren’s syndrome disease activity index and European League Against Rheumatism Sjögren’s syndrome patient-reported index: a complete picture of primary Sjögren’s syndrome patients. Arthritis Care Res 65:1358–1364. https://doi.org/10.1002/acr.21991CrossRefGoogle Scholar
Shiboski CH, Shiboski SC, Seror R et al (2016) 2016 American College of Rheumatology/European League Against Rheumatism classification criteria for primary Sjögren’s syndrome A consensus and data-driven methodology involving three international patient cohorts. Ann Rheum. https://doi.org/10.1136/annrheumdis-2016-210571 (Dis annrheumdis–2016–210571)Google Scholar
Jin L, Yu D, Li X et al (2014) CD4 + CXCR5+ follicular helper T cells in salivary gland promote B cells maturation in patients with primary Sjogren’s syndrome. Int J Clin Exp Pathol 7:1988–1996PubMedPubMedCentralGoogle Scholar
Lee K-E, Kang J-H, Yim Y-R et al (2017) Predictive significance of CCL21 and CXCL13 levels in the minor salivary glands of patients with Sjögren’s syndrome. Clin Exp Rheumatol 35(2):234–240PubMedGoogle Scholar
Hernández-Molina G, Michel-Peregrina M, Hernández-Ramírez DF et al (2011) Chemokine saliva levels in patients with primary Sjögren’s syndrome, associated Sjögren’s syndrome, pre-clinical Sjögren’s syndrome and systemic autoimmune diseases. Rheumatol Oxf Engl 50:1288–1292. https://doi.org/10.1093/rheumatology/ker019CrossRefGoogle Scholar